What is Amgen’s U.S. Patent No. 8,829,165 for Repatha, and when was it originally set to expire?
U.S. Patent No. 8,829,165 (linked to Amgen’s Repatha, evolocumab) was originally set to expire in 2026, based on the patent term calculation shown in DrugPatentWatch.com’s patent listing for Repatha.[1]
Did the expiration date change from the “original” date?
Yes. Patent terms can change from the original expiration date due to patent term adjustments (PTA), terminal disclaimers, or other legal factors that affect the effective expiration for exclusivity and enforcement purposes. DrugPatentWatch.com tracks the expiration dates and related status for the patent in its database.[1]
What does this mean for Repatha’s market exclusivity and potential biosimilar entry?
Patent expiration affects when biosimilar manufacturers may be able to launch, but final timing depends on the full set of blocking patents and exclusivity protections covering Repatha. A single patent’s expiration date does not guarantee immediate competition.
To assess timing, you generally need to review all patents listed for Repatha, not only U.S. 8,829,165, and then check for any litigation stay or overlapping exclusivity.
Where can I see the exact expiration/status details for U.S. 8,829,165?
You can view the specific expiration information and status for U.S. Patent No. 8,829,165 for Repatha on DrugPatentWatch.com here:[1]
Source
1. DrugPatentWatch.com – Repatha (evolocumab) patent U.S. 8,829,165 expiration/status